Cargando…
A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors
Undifferentiated carcinoma of the bladder is a rare malignancy with a poor prognosis. We present the case of an 81-year-old woman complaining of bladder irritation. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a bulky bladder tumor, which was diagnosed as cT4aN0M0. A transu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nagoya University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748333/ https://www.ncbi.nlm.nih.gov/pubmed/36544596 http://dx.doi.org/10.18999/nagjms.84.4.865 |
_version_ | 1784849803012734976 |
---|---|
author | Nakane, Wataru Naito, Yushi Morishita, Koya Matsuo, Kazuna Ishida, Shohei Matsukawa, Yoshihisa |
author_facet | Nakane, Wataru Naito, Yushi Morishita, Koya Matsuo, Kazuna Ishida, Shohei Matsukawa, Yoshihisa |
author_sort | Nakane, Wataru |
collection | PubMed |
description | Undifferentiated carcinoma of the bladder is a rare malignancy with a poor prognosis. We present the case of an 81-year-old woman complaining of bladder irritation. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a bulky bladder tumor, which was diagnosed as cT4aN0M0. A transurethral resection of the bladder tumor revealed pT2 or higher urothelial carcinoma. The patient underwent total cystectomy with an ileal conduit diversion. Histological examination revealed a primary undifferentiated bladder carcinoma with a sarcoma component, pT3aN0M0. Postoperative adjuvant chemotherapy with gemcitabine plus carboplatin was administered. However, this regimen was discontinued after one course due to significant myelosuppression. Four months after total cystectomy, a pelvic tumor with suspected local recurrence was detected on CT. The patient was diagnosed with recurrent undifferentiated carcinoma with a sarcoma component by a transperineal ultrasound-guided biopsy. Local radiation therapy and immunotherapy with immune checkpoint inhibitors were prescribed. After three courses of immunotherapy with pembrolizumab, the primary tumor disappeared. Upon continuing immune checkpoint inhibitor treatment, the patient has maintained a complete response without tumor recurrence in the following six months. |
format | Online Article Text |
id | pubmed-9748333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nagoya University |
record_format | MEDLINE/PubMed |
spelling | pubmed-97483332022-12-20 A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors Nakane, Wataru Naito, Yushi Morishita, Koya Matsuo, Kazuna Ishida, Shohei Matsukawa, Yoshihisa Nagoya J Med Sci Case Report Undifferentiated carcinoma of the bladder is a rare malignancy with a poor prognosis. We present the case of an 81-year-old woman complaining of bladder irritation. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a bulky bladder tumor, which was diagnosed as cT4aN0M0. A transurethral resection of the bladder tumor revealed pT2 or higher urothelial carcinoma. The patient underwent total cystectomy with an ileal conduit diversion. Histological examination revealed a primary undifferentiated bladder carcinoma with a sarcoma component, pT3aN0M0. Postoperative adjuvant chemotherapy with gemcitabine plus carboplatin was administered. However, this regimen was discontinued after one course due to significant myelosuppression. Four months after total cystectomy, a pelvic tumor with suspected local recurrence was detected on CT. The patient was diagnosed with recurrent undifferentiated carcinoma with a sarcoma component by a transperineal ultrasound-guided biopsy. Local radiation therapy and immunotherapy with immune checkpoint inhibitors were prescribed. After three courses of immunotherapy with pembrolizumab, the primary tumor disappeared. Upon continuing immune checkpoint inhibitor treatment, the patient has maintained a complete response without tumor recurrence in the following six months. Nagoya University 2022-11 /pmc/articles/PMC9748333/ /pubmed/36544596 http://dx.doi.org/10.18999/nagjms.84.4.865 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Case Report Nakane, Wataru Naito, Yushi Morishita, Koya Matsuo, Kazuna Ishida, Shohei Matsukawa, Yoshihisa A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors |
title | A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors |
title_full | A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors |
title_fullStr | A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors |
title_full_unstemmed | A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors |
title_short | A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors |
title_sort | case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748333/ https://www.ncbi.nlm.nih.gov/pubmed/36544596 http://dx.doi.org/10.18999/nagjms.84.4.865 |
work_keys_str_mv | AT nakanewataru acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT naitoyushi acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT morishitakoya acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT matsuokazuna acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT ishidashohei acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT matsukawayoshihisa acaseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT nakanewataru caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT naitoyushi caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT morishitakoya caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT matsuokazuna caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT ishidashohei caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors AT matsukawayoshihisa caseofundifferentiatedcarcinomaofthebladdertreatedbycombinationtherapyofsurgerylocalradiationandimmunecheckpointinhibitors |